Overview

A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study is to evaluate safety and tolerability of arbaclofen placarbil sustained release tablets taken every 12 hours compared to placebo in subjects with acute back spasms in the lumbar region.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Indivior Inc.
XenoPort, Inc.
Treatments:
Arbaclofen placarbil
Baclofen
Criteria
Inclusion Criteria:

1. Acute moderate to severe muscle spasms in the lumbar region, as indicated by a minimum
Visual Analog Scale pain severity score of 4.0 cm, beginning either:

- within four days prior to screening for subjects who do not require a 24-hour
washout

Or

- within three days for subjects who require a 24-hour washout

2. Willing to discontinue all analgesics (e.g. NSAIDS, COX-2 inhibitors, acetaminophen),
aspirin >81 mg/day, short-acting muscle relaxants (i.e. carisoprodol, Soma®), and
herbal remedies for pain at least 24 hours prior to first dose and to refrain from use
during the study (cardio-protective doses of aspirin ≤ 81 mg /day are allowed).

Exclusion Criteria:

1. Clinically significant abnormal neurological history or examination at screening
(excluding back spasm), including lumbar radicular symptoms, spinal stenosis, foot
drop, herniated nucleus pulposus, or other structural defects

2. Subjects with back spasm related to major trauma to the region

3. Subjects with muscle spasms due to a work-related injury or subjects involved in any
injury-related litigation

4. Subjects using any of the following medications at screening:

- Opioids, both short- and long-acting including but not limited to: morphine,
fentanyl patch, oxycodone, tramadol)

- benzodiazepines, such as valium and lorazepam

- cyclobenzaprine containing drugs (e.g., Flexeril, Amrix)

- carisoprodol (e.g., Soma®) within 24 hours of screening